Skip to main content
. 2020 May;33(2):165–174. doi: 10.2337/ds19-0031

FIGURE 2.

FIGURE 2

Recommendations for glucose-lowering therapy for type 2 diabetes. Reprinted with permission from ref. 6. ASCVD, atherosclerotic CVD; DPP-4i, dipeptidyl peptidase 4 inhibitor; eGFR, estimated glomerular filtration rate; GLP-1RA, glucagon-like peptide receptor agonist; HbA1C, hemoglobin A1C; SGLT2i, sodium-glucose cotransporter-2 inhibitor; SU, sulfonylurea; TZD, thiazolidinedione.